Disease Cell-Targeted Precision Medicine

Ashvattha Therapeutics is leveraging its hydroxyl dendrimer (HD) platform to develop a new class of precision medicines that selectively treat diseased cells in regions of inflammation. By making precision medicine even more precise, our platform has the potential to change the standard of care across ophthalmology, neurology, inflammatory diseases and neuro-oncology.​

Welcome to Ashvattha

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel HD therapeutics (HDTs) to treat unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. Our HD platform builds therapeutics that are selectively taken up only by inflamed tissues, allowing us to treat diseases with unprecedented precision.

Jeffrey Cleland, Ph.D., Ashvattha Chairman, CEO and President interview with Health Professional Radio, July 1, 2021

"Potential COVID Treatments That Address Brain Inflammation"

We have designed and optimized an HDT that precisely targets reactive macrophages. microglia and retinal pigment epithelial cells (RPEs) after systemic administration

Our solution enables patient selection followed by treatment with anti-neuroinflammatory agent coupled to HDT to target reactive microglia

OP-101 selectively targets pro-inflammatory macrophages and microglia responsible for excessive cytokine production

We are developing HDTs leveraging our ability to target tumor associated macrophages (TAMs)

Pipeline: Value-Creating Outcomes

Latest News